All In Biotech

Drug Trial Radar · NCT07160634

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Oct 22, 2025

Primary completion

Jan 2029

Study completion Jan 2034

Sponsor

Lead sponsor
Solid Biosciences Inc.Industry
Sponsor type
Industry
First posted
Sep 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 7 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, double-blind, placebo-controlled study with the primary objective of evaluating the efficacy of a single IV infusion of SGT-003 in pediatric ambulant male participants with DMD. The secondary objectives include the evaluation of additional efficacy and safety outcomes. The study will be divided into 2 parts. Participants will be randomized 1:1 to either SGT-003 in Part 1 followed by placebo in Part 2 or to placebo in Part 1 followed by SGT-003 in Part 2. Participants will continue to be monitored in long term follow up (LTFU) for at least 5 years from their SGT-003 dosing date.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • SGT-003Drug

    Adeno-associated virus (AAV)-based gene therapy that delivers a codon-optimized and CpG island-minimized human 5-repeat microdystrophin (h-μD5)

  • PlaceboDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Time to Rise (TTR) from Supine Velocity (rise/s) at Day 540Time frame: Baseline, Day 540

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Not yet recruiting

  • Neurology Rare Disease Center

    Flower Mound, Texas · Not yet recruiting

  • Children's Hospital of the King's Daughters

    Norfolk, Virginia · Not yet recruiting

  • The Children's Hospital of Westmead

    Sydney, New South Wales, Australia · Recruiting

  • Alberta Children's Hospital

    Calgary, Alberta, Canada · Recruiting

  • BC Children's Hospital

    Vancouver, British Columbia, Canada · Recruiting

  • The Hospital for Sick Children (SickKids)

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.